{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:14:34Z","timestamp":1787238874728,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T00:00:00Z","timestamp":1257984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusion for patients taking dasatinib. Should pleural effusion develop, dasatinib should be interrupted until the condition resolves. Patients with a history of pleural effusion risk factors should be monitored closely while taking dasatinib. Patients receiving imatinib and nilotinib are not without risk of fluid retention. All patients should also be educated to recognize and report key symptoms of fluid retention or pleural effusion. Pleural effusions are generally managed by dose interruption\/reduction and other supportive measures in patients with chronic myeloid leukemia receiving dasatinib therapy.<\/jats:p>","DOI":"10.1186\/1756-8722-2-46","type":"journal-article","created":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T14:42:36Z","timestamp":1258036956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib"],"prefix":"10.1186","volume":"2","author":[{"given":"David","family":"Masiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Gerry","family":"Gorospe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen S","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,12]]},"reference":[{"key":"73_CR1","unstructured":"National Cancer Institute. US National Institutes of Health: Surveillance Epidemiology and End Results web site: Finding Cancer Statistics: Cancer Stat Fact Sheets: Chronic Myeloid Leukemia. National Cancer Institute, Accessed August 20, 2008, [http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html]"},{"key":"73_CR2","unstructured":"National Comprehensive Cancer Network (NCCN): Chronic myelogenous leukemia V.2.2009. NCCN Clinical Practice Guidelines in Oncology. Accessed September 20, 2009, [http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf]"},{"issue":"17","key":"73_CR3","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL: Chronic myeloid leukemia. N Engl J Med. 1999, 340 (17): 1330-1340. 10.1056\/NEJM199904293401706.","journal-title":"N Engl J Med"},{"issue":"5940","key":"73_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"CR Bartram","year":"1983","unstructured":"Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983, 306 (5940): 277-280. 10.1038\/306277a0.","journal-title":"Nature"},{"issue":"1","key":"73_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld : Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984, 36 (1): 93-99. 10.1016\/0092-8674(84)90077-1.","journal-title":"Cell"},{"issue":"4946","key":"73_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990, 247 (4946): 1079-1082. 10.1126\/science.2408149.","journal-title":"Science"},{"issue":"1 Suppl 1","key":"73_CR7","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","volume":"44","author":"RH Alvarez","year":"2007","unstructured":"Alvarez RH, Kantarjian H, Cortes JE: The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007, 44 (1 Suppl 1): S4-S14. 10.1053\/j.seminhematol.2006.12.007.","journal-title":"Semin Hematol"},{"issue":"12","key":"73_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J: New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006, 145 (12): 913-923.","journal-title":"Ann Intern Med"},{"issue":"23","key":"73_CR9","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355 (23): 2408-2417. 10.1056\/NEJMoa062867.","journal-title":"N Engl J Med"},{"issue":"1","key":"73_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","volume":"20","author":"T Hughes","year":"2006","unstructured":"Hughes T, Branford S: Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006, 20 (1): 29-41. 10.1016\/j.blre.2005.01.008.","journal-title":"Blood Rev"},{"key":"73_CR11","doi-asserted-by":"crossref","unstructured":"O'Brien SG, Guilhot F, Goldman JM: International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract 186]. Blood. 2008, 112 (11):","DOI":"10.1182\/blood.V112.11.186.186"},{"issue":"15s","key":"73_CR12","first-page":"391s","volume":"26","author":"JL Steegman","year":"2008","unstructured":"Steegman JL, Michallet M, Morra E, Marin D, Ossenkoppele GJ, Verhoef G, K\u00fchr T, Bj\u00f6reman M, Sterckx M, Cerri K: Imatinib use in chronic phase CML in clinical practice: the UNIC study [abstract 7077]. J Clin Oncol. 2008, 26 (15s): 391s-","journal-title":"J Clin Oncol"},{"key":"73_CR13","unstructured":"Nilotinib prescribing information. 2007, East Hanover, NJ: Novartis Pharmaceuticals Corporation, [http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf]"},{"key":"73_CR14","unstructured":"Dasatinib prescribing information. 2009, Princeton, NJ: Bristol-Myers Squibb Company, [http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf]"},{"issue":"27","key":"73_CR15","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004, 47 (27): 6658-6661. 10.1021\/jm049486a.","journal-title":"J Med Chem"},{"issue":"11","key":"73_CR16","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O'Hare","year":"2005","unstructured":"O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65 (11): 4500-4505. 10.1158\/0008-5472.CAN-05-0259.","journal-title":"Cancer Res"},{"issue":"7","key":"73_CR17","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007, 110 (7): 2242-2249. 10.1182\/blood-2007-03-066936.","journal-title":"Blood"},{"issue":"8","key":"73_CR18","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007, 109 (8): 3207-3213. 10.1182\/blood-2006-09-046888.","journal-title":"Blood"},{"issue":"10","key":"73_CR19","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007, 109 (10): 4143-4150. 10.1182\/blood-2006-09-046839.","journal-title":"Blood"},{"issue":"6","key":"73_CR20","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP: Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007, 109 (6): 2303-2309. 10.1182\/blood-2006-09-047266.","journal-title":"Blood"},{"issue":"15s","key":"73_CR21","first-page":"374s","volume":"26","author":"MJ Mauro","year":"2008","unstructured":"Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub Y, Sinha R, Stone RM: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract 7009]. J Clin Oncol. 2008, 26 (15s): 374s-","journal-title":"J Clin Oncol"},{"issue":"19","key":"73_CR22","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, R\u00e9a D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008, 26 (19): 3204-3212. 10.1200\/JCO.2007.14.9260.","journal-title":"J Clin Oncol"},{"issue":"15s","key":"73_CR23","first-page":"375s","volume":"26","author":"HJ Khoury","year":"2008","unstructured":"Khoury HJ, Goldberg SL, Mauro M, Stone RM, Matloub Y, Chen T, Guilhot F: Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety [abstract 7015]. J Clin Oncol. 2008, 26 (15s): 375s-","journal-title":"J Clin Oncol"},{"issue":"5","key":"73_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","volume":"141","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, Chaidos A, Olavarria E, Goldman JM, Apperley JF, Marin D: Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008, 141 (5): 745-747. 10.1111\/j.1365-2141.2008.07108.x.","journal-title":"Br J Haematol"},{"issue":"25","key":"73_CR25","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007, 25 (25): 3908-3914. 10.1200\/JCO.2007.12.0329.","journal-title":"J Clin Oncol"},{"issue":"8","key":"73_CR26","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","volume":"176","author":"A Bergeron","year":"2007","unstructured":"Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P: Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007, 176 (8): 814-818. 10.1164\/rccm.200705-715CR.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"73_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","volume":"127","author":"S Blake","year":"2008","unstructured":"Blake S, Hughes TP, Mayrhofer G, Lyons AB: The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 2008, 127 (3): 330-339. 10.1016\/j.clim.2008.02.006.","journal-title":"Clin Immunol"},{"issue":"12","key":"73_CR28","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, K\u00f6cher T, Superti-Furga G: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007, 110 (12): 4055-4063. 10.1182\/blood-2007-07-102061.","journal-title":"Blood"},{"issue":"11","key":"73_CR29","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1586\/14737140.7.11.1529","volume":"7","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A: Management of Bcr-Abl-positive leukemias with dasatinib. Expert Rev Anticancer Ther. 2007, 7 (11): 1529-1536. 10.1586\/14737140.7.11.1529.","journal-title":"Expert Rev Anticancer Ther"},{"key":"73_CR30","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007, 110: 3540-3546. 10.1182\/blood-2007-03-080689.","journal-title":"Blood"},{"issue":"suppl 1","key":"73_CR31","first-page":"557","volume":"92","author":"P Le Coutre","year":"2007","unstructured":"Le Coutre P, Larson R, Kantarjian H: A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase. Haematologica. 2007, 92 (suppl 1): 557-","journal-title":"Haematologica"},{"issue":"suppl 1","key":"73_CR32","first-page":"556","volume":"92","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Larson R, Kantarjian H: Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis or relapsed\/refractory Ph+ acute lymphoblastic leukemia. Haematologica. 2007, 92 (suppl 1): 556-","journal-title":"Haematologica"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-2-46.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-2-46\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-2-46.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:12:11Z","timestamp":1630469531000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-2-46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-2-46","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,12]]},"assertion":[{"value":"28 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"46"}}